Details for New Drug Application (NDA): 050019
✉ Email this page to a colleague
NDA 050019 describes PENBRITIN, which is a drug marketed by Wyeth Ayerst and is included in three NDAs. Additional details are available on the PENBRITIN profile page.
The generic ingredient in PENBRITIN is ampicillin sodium. There are seventy drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the ampicillin sodium profile page.
The generic ingredient in PENBRITIN is ampicillin sodium. There are seventy drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the ampicillin sodium profile page.
Summary for 050019
| Tradename: | PENBRITIN |
| Applicant: | Wyeth Ayerst |
| Ingredient: | ampicillin/ampicillin trihydrate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | FOR SUSPENSION;ORAL | Strength | EQ 100MG BASE/ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | FOR SUSPENSION;ORAL | Strength | EQ 125MG BASE/5ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | FOR SUSPENSION;ORAL | Strength | EQ 250MG BASE/5ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
